The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Multidrug- and extensively drug-resistant tuberculosis have emerged as grave threats to public health worldwide. Very few active drugs are available or likely to become available soon. To address these problems we revisited a classical observation, the applicability of phenothiazines as antimicrobial drugs. Within this pharmacological class we selected thioridazine, which is most efficacious and least toxic, when used as an antipsychotic drug. We tested thioridazine monotherapy in the Balb/c mouse model for its activity to treat both susceptible and multidrug-resistant tuberculosis by a two months daily oral administration of 32 and 70 mg/kg. In addition, we tested its additive value when combined with a standard first-line regimen for susceptible tuberculosis. Thioridazine treatment resulted in a significant reduction of colony-forming-units of the susceptible (-4.4 log CFU, p<0.05) and multidrug-resistant tuberculosis bacilli (-2.4 log CFU, p<0.009) in the lung both at one and two months after infection, compared to controls. Moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (-6.2 vs -5.9 log CFU, p<0.01). Thioridazine may represent an effective compound for treatment of susceptible and multidrug-resistant tuberculosis. The phenothiazines and their targets represent interesting novel opportunities in the search for antituberculosis drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration
Sohaskey, C. D. (2008) · Journal of Bacteriology · doi:10.1128/jb.01857-07 · Cited by 108 · cited 2×
“In stage 2, the actual pathway of action remains unknown [19].”
Cited by
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
van Ingen, J., Boeree, M. J., van Soolingen, D., & Mouton, J. W. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.04.001 · Cited by 351
Self-citationFinding alternatives to antibiotics
Allen, H. K., Trachsel, J., Looft, T., & Casey, T. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12468 · Cited by 269
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen
Ramón-García, S., Ng, C., Anderson, H., Chao, J. D., Zheng, X., Pfeifer, T., Av-Gay, Y., Roberge, M., & Thompson, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-11 · Cited by 185
Addressing the tuberculosis–depression syndemic to end the tuberculosis epidemic
Sweetland, A. C., Kritski, A., Oquendo, M. A., Sublette, M. E., Norcini Pala, A., Silva, L. R. B., Karpati, A., Silva, E. C., Moraes, M. O., Silva, J. R. L. E., et al. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0584 · Cited by 177
Metadata
- Authors
- van Soolingen, D., Hernandez-Pando, R., Orozco, H., Aguilar, D., Magis-Escurra, C., Amaral, L., van Ingen, J., & Boeree, M. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-09-09
- Volume
- 5
- Issue
- 9
- Pages
- e12640
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2060712419
- Cited by
- 96
- References
- 1
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.